The Department of Biotechnology (DBT) today announced the scientific completion of India’s first indigenously developed quadrivalent Human Papillomavirus (qHPV) vaccine (types 6,11,16 and 18), for prevention of Cervical Cancer and Genital Warts. The HPV vaccine has been developed by the Serum Institute of India Pvt Ltd. and will be launched soon. The vaccine received marketing authorization approval from the Drug Controller General of India (DCGI) on 12th July 2022. The development of the vaccine has been supported by the DBT through Grand Challenges India, implemented by the Biotechnology Industry Research Assistance Council (BIRAC).
